HomeAI · summaries
Storia in 2 fonti
ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy
At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching
Roivant's autoimmune drug approval, Cytokinetics reports full data for heart condition treatment, and more biotech news
- ·
Alnylam defends heart disease drugs after failure of AstraZeneca’s Wainua
An AstraZeneca heart disease trial failure has put Alnylam under pressure. It's mounting a defense of its medicines.
